News | Contrast Media | December 09, 2016

Bracco Diagnostics Highlights Contrast Media Milestones at RSNA 2016

Company received several key FDA approvals, including first contrast agent for liver ultrasound in adult and pediatric patients, first syringe-less power injector

 

contrast media

At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased a review of key milestones the company has achieved this year in diagnostic imaging and contrast media.

The following summary provides a snapshot of major milestones impacting Bracco this year:

  • U.S. Food and Drug Administration (FDA) approval and recent launch of the first and only syringe-less power injector in the United States, designed to streamline workflow and improve patient care for computed tomography (CT);
  • The company received the first FDA approval for contrast-enhanced ultrasonography of the liver in adult and pediatric patients — the first ultrasound contrast agent approved for use in pediatrics in the world. This year, the Centers for Medicare & Medicaid Services approved coverage and coding for abdominal ultrasound with contrast under the Hospital Outpatient Prospective Payment System;
  • The company received the first and only FDA approvals of two of its barium-based products (one for CT; one for contrast radiography);
  • The company received an Innovative Technology Designation from Vizient for its injectable suspension for contrast echocardiography; and
  • Virtual colonoscopy received the highest grade from the U.S. Preventive Services Task Force as an alternative screening tool in detecting colorectal cancer. The recommendation was made after the task force found that CT colonography was proven to reduce the incidence and mortality of colorectal cancer, the second deadliest cancer in the U.S. Bracco markets the latest CO2 insufflator and a stool marker, or "fecal tagging" agent, for CT colonoscopy.

For more information: www.imaging.bracco.com/us-en

Related Content

Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
Displacement comparison at the end-systolic frame and final frame

Displacement comparison at the end-systolic frame and final frame. The three patients (V6, V10, V16) with different left-ventricle walls are shown. Point-to-surface distance is a measure to estimate the distance of a point from the reference surface. Image courtesy of WMG, University of Warwick

News | Cardiac Imaging | August 28, 2019
A new 3-D magnetic resonance imaging (MRI) computing technique developed by scientists in WMG at the University of...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension
Technology | Contrast Media | August 05, 2019
Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.